MIRAMAR, Fla., Jan. 17, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is pleased to announce that their subsidiary, Olaregen Therapeutix, Inc., is introducing an exciting new product, Excellagen Aesthetics™ for the cosmetic surgery and aesthetic dermatology market. FDA 510(k) cleared with an indication for the management of wounds, Excellagen Aesthetics™ is intended for use following facial rejuvenation procedures, including post-laser surgery, post-chemical peels, and post- skin ablation. Excellagen is a ready to use 3-dimensional wound conforming matrix that supports a favorable wound healing environment. It is designed to activate collagen, accelerate granulation, and promote new tissue growth by providing a structural scaffold for cellular migration and proliferation. Excellagen Aesthetics™ has been shown in vitro to trigger the localized release of endogenous growth factors including Platelet-Derived Growth Factor (PDGF), a key biological mediator of wound healing.
Olaregen is rolling out Excellagen Aesthetics™ with a dedicated contract sales force uniquely positioned in major metropolitan areas across the United States where the majority of aesthetic dermatology procedures are clustered. Americans spent an estimated $8 billion on surgical and non-surgical aesthetic dermatology procedures in 2018 when there were over 340,000 facial rejuvenation performed.
Scott Emmens, Senior Vice President of Sales and Business Development at Olaregen commented, “We have been working closely with the aesthetic dermatology community, and Excellagen Aesthetics™ is being tested with some leading dermatologists who are conducting case studies to evaluate the efficacy of our cellular tissue product in wound management as measured by patient reported down-time as well as patient satisfaction with post-treatment care. We are enthusiastic about the early response from patients and doctors who have tried the product after facial rejuvenation procedures including micro-needling and laser skin resurfacing, two procedures that result in post-treatment pain and significant healing times that limit daily activities. We look forward to engaging with the dermatology community to introduce Excellagen Aesthetics™ and show how our FDA-cleared product can be used to the benefit of their patients and their practice
Olaregen is rolling out Excellagen Aesthetics™ with a dedicated contract sales force uniquely positioned in major metropolitan areas across the United States where the majority of aesthetic dermatology procedures are clustered. Americans spent an estimated $8 billion on surgical and non-surgical aesthetic dermatology procedures in 2018 when there were over 340,000 facial rejuvenation performed.
Scott Emmens, Senior Vice President of Sales and Business Development at Olaregen commented, “We have been working closely with the aesthetic dermatology community, and Excellagen Aesthetics™ is being tested with some leading dermatologists who are conducting case studies to evaluate the efficacy of our cellular tissue product in wound management as measured by patient reported down-time as well as patient satisfaction with post-treatment care. We are enthusiastic about the early response from patients and doctors who have tried the product after facial rejuvenation procedures including micro-needling and laser skin resurfacing, two procedures that result in post-treatment pain and significant healing times that limit daily activities. We look forward to engaging with the dermatology community to introduce Excellagen Aesthetics™ and show how our FDA-cleared product can be used to the benefit of their patients and their practice
1
